You are viewing the site in preview mode
Skip to main content
| |
total a)
|
Benign and malignant breast neoplasms
|
|---|
|
n
|
ROR (95%CI)
|
PRR (X2)
|
IC (95%CI)
|
|---|
|
Typical antipsychotic
|
| |
Haloperidol
|
939
|
1
|
0.49 (0.07, 3.51)
|
0.49 (0.13)
|
−0.60 (−5.30, 4.11)
|
|
Bromperidol
|
113
|
1
|
4.14 (0.58, 29.68)
|
4.11 (0.27)
|
0.58 (−4.06, 5.43)
|
|
Pipamperone
|
15
|
0
|
–
|
–
|
–
|
|
Spiperone
|
0
|
0
|
–
|
–
|
–
|
|
Timiperone
|
9
|
0
|
–
|
–
|
–
|
|
Propericiazine
|
85
|
0
|
–
|
–
|
–
|
|
Prochlorperazine
|
143
|
0
|
–
|
–
|
–
|
|
Perphenazine
|
17
|
0
|
–
|
–
|
–
|
|
Fluphenazine
|
89
|
0
|
–
|
–
|
–
|
|
Levomepromazine
|
730
|
0
|
–
|
–
|
–
|
|
Chlorpromazine
|
431
|
0
|
–
|
–
|
–
|
|
Sulpiride
|
1395
|
12
|
4.05 (2.29, 7.16)*
|
4.02 (24.15)*
|
1.70 (−0.16, 3.56)
|
|
Sultopride
|
52
|
0
|
–
|
–
|
–
|
|
Nemonapride
|
9
|
0
|
–
|
–
|
–
|
| |
Pimozide
|
39
|
0
|
–
|
–
|
–
|
|
Atypical antipsychotic
|
| |
Perospirone
|
416
|
0
|
–
|
–
|
–
|
|
Risperidone
|
2629
|
11
|
1.95 (1.08, 3.54)*
|
1.95 (4.17)
|
0.84 (−1.08, 2.78)
|
|
Paliperidone
|
774
|
2
|
2.37 (0.59, 9.53)
|
2.37 (0.51)
|
0.70 (−3.16, 4.55)
|
|
Blonanserin
|
550
|
4
|
3.4 (1.27, 9.11)*
|
3.39 (4.54)*
|
1.19 (−1.80, 4.19)
|
|
Olanzapine
|
1825
|
2
|
0.51 (0.07, 3.51)
|
0.5 (0.52)
|
−0.72 (−4.56, 3.13)
|
|
Quetiapine
|
1836
|
0
|
–
|
–
| |
|
Clozapine
|
1283
|
11
|
4.03 (2.22, 7.31)*
|
4.01 (21.77)*
|
1.67 (−0.26, 3.61)
|
|
Asenapine
|
134
|
0
|
–
|
–
|
–
|
|
Aripiprazole
|
2316
|
6
|
1.36 (0.61, 3.03)
|
1.36 (0.26)
|
0.37 (−2.15, 2.89)
|
|
Brexpiprazole
|
112
|
0
|
–
|
–
|
–
|
|
Zotepine
|
279
|
5
|
8.48 (3.50, 20.58)*
|
8.35 (25.39)*
|
1.94 (−0.84, 4.65)
|
|
Mosapramine
|
4
|
0
|
–
|
–
|
–
|
|
Oxypertine
|
6
|
0
|
–
|
–
|
–
|
|
Clocapramine
|
0
|
0
|
–
|
–
|
–
|
- ROR: the reporting odds ratio, PRR: the proportional reporting ratio, IC: the information component, CI: the confidence interval
- a) total number of reports from April 2004 to April 2019 in JADER
- An asterisk(*) indicates that the adverse events are detected as signals
